Name	Acute kidney failure
ICD	ICD-11: GB60

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	Meclofenamic acid increased Cellular tumor antigen p53 (TP53/p53) mRNA and protein levels in AKI both in vitro and in vivo, and FTO overexpression reduced p53 expression and reversed the MA-induced p53 increase in cisplatin-induced acute kidney injury Acute kidney injury.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Cisplatin		Approved	Drug Info
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Apoptosis			hsa04210
Cell Process	Cell apoptosis
In-vitro Model	HK2	Normal	Acipenser baerii	CVCL_YE28
In-vivo Model	Induced AKI in c57BL/6 mice by intraperitoneal cisplatin injection and treated the animal with vehicle or an FTO inhibitor meclofenamic acid (MA) for 3 days.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[1]
Response Summary	Meclofenamic acid increased Cellular tumor antigen p53 (TP53/p53) mRNA and protein levels in AKI both in vitro and in vivo, and FTO overexpression reduced p53 expression and reversed the MA-induced p53 increase in cisplatin-induced Acute kidney injury.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Meclofenamic acid		Approved	Drug Info
Target Regulator	Fat mass and obesity-associated protein (FTO)		ERASER	Regulator Info
Target Regulation	Down regulation
Pathway Response	Apoptosis			hsa04210
Cell Process	Cell apoptosis
In-vitro Model	HK2	Normal	Acipenser baerii	CVCL_YE28
In-vivo Model	Induced AKI in c57BL/6 mice by intraperitoneal cisplatin injection and treated the animal with vehicle or an FTO inhibitor meclofenamic acid (MA) for 3 days.

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in Fibrinogen alpha chain (FGA) and Havcr1 protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Cisplatin		Approved	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in Fibrinogen alpha chain (FGA) and Havcr1 protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Berberine		Phase 4	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in FGA and Hepatitis A virus cellular receptor 1 (HAVCR1) protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Cisplatin		Approved	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in FGA and Hepatitis A virus cellular receptor 1 (HAVCR1) protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Berberine		Phase 4	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).

In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Solute carrier family 12 member 1 (SLC12A1) protein levels and a decrease in FGA and Havcr1 protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Cisplatin		Approved	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene				[3]
Response Summary	m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Solute carrier family 12 member 1 (SLC12A1) protein levels and a decrease in FGA and Havcr1 protein levels. However, berberine pretreatment reversed these effects.
Responsed Disease	Acute kidney failure [ICD-11: GB60]
Responsed Drug	Berberine		Phase 4	Drug Info
Cell Process	Metabolic processes
	Cell death
	Cell apoptosis
In-vivo Model	This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG).

Ref 1	Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m(6)A abrogation in RNA. J Biol Chem. 2019 Nov 8;294(45):16908-16917. doi: 10.1074/jbc.RA119.011009. Epub 2019 Oct 2.
Ref 2	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
Ref 3	Integrated Analysis of m6A Methylome in Cisplatin-Induced Acute Kidney Injury and Berberine Alleviation in Mouse. Front Genet. 2020 Nov 20;11:584460. doi: 10.3389/fgene.2020.584460. eCollection 2020.
Ref 4	ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007 Mar;26(1):39-57. doi: 10.1007/s10555-007-9042-6.
Ref 5	National Cancer Institute Drug Dictionary (drug name INCB086550).
Ref 6	Clinical pipeline report, company report or official report of AstraZeneca (2009).